Inbiose is a leading B2B Biotech Company specializing in the development of specialty glycans, particularly Human Milk Oligosaccharides (HMOs). With a proven track record in large-scale HMO production, Inbiose utilizes its proprietary GlycoActives® technology. Founded in 2013 as a spinoff from the University of Ghent, Inbiose has become the largest private research group worldwide for specialty glycans.

Their focus lies in developing specialty glycans that have a direct or indirect impact on health, through the modulation of the microbiome. Inbiose continuously enhances its technology platform by incorporating the latest biotech, bio-informatics, and health science advancements. The company strives to make these specialty glycans readily available for mainstream applications, minimizing time to market for the benefit of all.

With a team of 50 highly skilled individuals, mainly consisting of bio-engineers and bio-informatics, Inbiose operates from its offices and lab in Ghent, Belgium